Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis.

Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med (2014) 3.46

Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol (2013) 1.48

Plasma viscosity in giant cell arteritis as a predictor of disease activity. Ann Rheum Dis (1993) 0.97

Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol (2013) 0.96

Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep (2011) 0.94

Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Clin Rheumatol (2014) 0.89

Urinary IL-6: a marker for mesangial proliferative glomerulonephritis? Clin Exp Immunol (1991) 0.86

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis. RMD Open (2016) 0.81

T cell-macrophage interactions and granuloma formation in vasculitis. Front Immunol (2014) 0.80

Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis (1995) 0.79

[Giant cell arteritis (temporal arteritis). Pathophysiology, immunology]. Ophthalmologe (2006) 0.78

Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis (1996) 0.78

Activity of the neuroendocrine axes in patients with polymyalgia rheumatica before and after TNF-α blocking etanercept treatment. Arthritis Res Ther (2012) 0.77

Selective T cell receptor decrease in peripheral blood T lymphocytes of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis (2004) 0.76

Polymyalgia rheumatica following robotic radical prostatectomy. Int J Surg Case Rep (2012) 0.75

Antibodies to intermediate filaments in polymyalgia rheumatica/giant cell arteritis: do they reflect the underlying disease activity rather than the acute phase response? Ann Rheum Dis (1994) 0.75

High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins. Arthritis Res Ther (2015) 0.75

Bone loss and glucocorticoid therapy in patients with respiratory disease. Thorax (1999) 0.75

Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol (2017) 0.75

Tocilizumab (Actemra). Hum Vaccin Immunother (2017) 0.75

Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med (2001) 7.41

"Lymphokines": non-antibody mediators of cellular immunity generated by lymphocyte activation. Nature (1969) 6.42

Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J (1978) 4.29

Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum (1992) 3.92

An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol (1982) 3.05

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75

The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum (1992) 2.68

The sensitivity and specificity of reduced CD8 lymphocyte levels in the diagnosis of polymyalgia rheumatica/giant cell arteritis. Clin Exp Rheumatol (1994) 2.61

HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A (1989) 2.60

A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide. J Immunol (1990) 2.55

HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med (1980) 2.52

Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum (1992) 2.31

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25

Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol (1984) 2.17

A role for purine metabolism in the immune response: Adenosine-deaminase activity and deoxyadenosine catabolism. Lancet (1978) 2.15

Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis (1993) 2.01

Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol (1984) 1.95

D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69

Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis (1989) 1.68

IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Scand J Rheumatol (1983) 1.67

B lymphocyte alloantigens in the study of the genetic basis of rheumatoid arthritis. Ann Rheum Dis (1977) 1.65

Analysis of T cell subsets in the peripheral blood and synovial fluid of patients with rheumatoid arthritis by means of monoclonal antibodies. Ann Rheum Dis (1983) 1.64

The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol (2001) 1.62

Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol (1993) 1.57

Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study. Ann Rheum Dis (1987) 1.54

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol (1995) 1.49

Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis (1994) 1.44

Influence of pregnancy on disease activity in a patient with palindromic rheumatism. J Rheumatol (1992) 1.38

ELISA assays for IgM and IgG rheumatoid factors. J Immunol Methods (1982) 1.37

Selective migration of the human helper-inducer memory T cell subset: confirmation by in vivo cellular kinetic studies. Eur J Immunol (1991) 1.34

Circadian variation in disease activity in rheumatoid arthritis. Br Med J (Clin Res Ed) (1982) 1.30

Human pregnancy serum inhibits interleukin-2 production. Clin Exp Immunol (1984) 1.29

HLA-DRw4 and rheumatoid arthritis. Lancet (1979) 1.29

Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome. Hum Immunol (1991) 1.27

Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Ann Rheum Dis (1983) 1.23

Evidence for the continuous recruitment and activation of T cells into the joints of patients with rheumatoid arthritis. Eur J Immunol (1994) 1.22

Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun (2000) 1.21

Disease activity and pregnancy associated alpha 2-glycoprotein in rheumatoid arthritis during pregnancy. Br Med J (Clin Res Ed) (1983) 1.20

Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol (1990) 1.20

Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter's disease. Arthritis Rheum (1991) 1.19

The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) (2002) 1.19

Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis (1983) 1.19

Activated T lymphocytes of the synovial membrane in rheumatoid arthritis and other arthropathies. Scand J Immunol (1985) 1.19

Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology (1988) 1.15

Sequence analysis of HLA-DR4B1 subtypes: additional first domain variability is detected by oligonucleotide hybridization and nucleotide sequencing. Hum Immunol (1990) 1.14

In vivo analysis of disease modifying drug therapy activity in rheumatoid arthritis by sequential immunohistological analysis of synovial membrane interleukin 1 beta. J Rheumatol (1994) 1.13

Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J Rheumatol (1991) 1.12

Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum (2002) 1.12

Expression of HLA-DR, DQ and DP antigens and interleukin-2 receptor on synovial fluid T lymphocyte subsets in rheumatoid arthritis: evidence for "frustrated" activation. J Rheumatol (1987) 1.11

Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis? Clin Exp Immunol (2011) 1.10

Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum (2001) 1.09

Response of rheumatoid-synovial-fluid lymphocytes to non-specific mitogens. Lancet (1973) 1.07

Lymphocyte studies in rheumatoid arthritis. III. A comparative study of the responses of peripheral blood and synovial fluid lymphocytes to phytomitogens. Scand J Rheumatol (1979) 1.07

A combined immunohistological and histochemical analysis of lymphocyte and macrophage subpopulations in the rheumatoid nodule. Clin Exp Immunol (1984) 1.05

Detection of immune complexes in serum of patients with ankylosing spondylitis. Ann Rheum Dis (1978) 1.05

Cytokines and the chronic inflammation of rheumatic disease. II. The presence of interleukin-2 in synovial fluids. Clin Exp Immunol (1984) 1.04

Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis (1981) 1.03

Histocompatibility antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol (1983) 1.02

Action of chloroquine phosphate in rheumatoid arthritis. 1. Immunosuppressive effect. Ann Rheum Dis (1973) 1.02

HLA-DR4 restricted lymphocyte proliferation to a Mycobacterium tuberculosis extract in rheumatoid arthritis and healthy subjects. J Immunol (1988) 1.02

Clotrimazole in rheumatoid arthritis. Ann Rheum Dis (1980) 1.02

Serum and secretory IgA immune response to Klebsiella pneumoniae in ankylosing spondylitis. Clin Rheumatol (1983) 1.01

Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) (2000) 1.00

Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum (1995) 1.00

An improved method for sacro-iliac joint imaging: a study of normal subjects, patients with sacro-iliitis and patients with low back pain. Clin Radiol (1981) 0.99

Simultaneous ligation of CD5 and CD28 on resting T lymphocytes induces T cell activation in the absence of T cell receptor/CD3 occupancy. J Immunol (1993) 0.99

Changes in immune function in patients with rheumatoid arthritis following treatment with sodium aurothiomalate. Ann Rheum Dis (1981) 0.99

Does rheumatoid arthritis have a clinicopathological spectrum similar to that of leprosy? Ann Rheum Dis (1982) 0.98

Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) (2002) 0.98

Abnormal helper-inducer/suppressor-inducer T-cell subset distribution and T-cell activation status are common to all types of chronic synovitis. Scand J Immunol (1988) 0.98

Carcinoembryonic antigen in rheumatoid arthritis. Lancet (1974) 0.98

Atopy and rheumatoid arthritis. Clin Allergy (1985) 0.98

Abnormal lymphocyte reactivity to self-major histocompatibility antigens in rheumatoid arthritis. J Rheumatol (1987) 0.97

Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol (1993) 0.97

Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor. Ann Rheum Dis (1980) 0.97

Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum (1996) 0.97

Functional assay of cytotoxic lymphocytes involved in antibody-mediated cytotoxicity in normal and rheumatoid subjects. Ann Rheum Dis (1977) 0.97

Trauma and seronegative spondyloarthropathy. Ann Rheum Dis (1989) 0.96

Deficient sulphoxidation status and D-penicillamine toxicity. Lancet (1983) 0.96

The inhibition of NK cell function by azathioprine during the treatment of patients with rheumatoid arthritis. Br J Rheumatol (1990) 0.95

Immunogenetic and cellular immune mechanisms in rheumatoid arthritis: relevance to new therapeutic strategies. Br J Rheumatol (1990) 0.95

Inhibition of interleukin-2 production by retroplacental sera: a possible mechanism for human fetal allograft survival. Am J Reprod Immunol Microbiol (1985) 0.95

Enhanced T helper cell function for the spontaneous production of IgM rheumatoid factor in vitro in rheumatoid arthritis. Clin Exp Immunol (1984) 0.95

The large granular lymphocyte syndrome with rheumatoid arthritis. Immunogenetic evidence for a broader definition of Felty's syndrome. Arthritis Rheum (1994) 0.95

Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1. J Rheumatol (1991) 0.94

Delayed cutaneous hypersensitivity in rheumatoid arthritis: the influence of nutrition and drug therapy. Clin Rheumatol (1984) 0.93

HLA class II and T cell receptor gene polymorphisms in psoriatic arthritis and psoriasis. J Rheumatol (1990) 0.93

Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum (1996) 0.93

Large granular lymphocyte expansions in patients with Felty's syndrome: analysis using anti-T cell receptor V beta-specific monoclonal antibodies. Clin Exp Immunol (1995) 0.93

Cytology of rheumatoid synovial cells in culture. II. Association of polykarocytes with rheumatoid and other forms of arthritis. Ann Rheum Dis (1974) 0.93

Spontaneous and pokeweed mitogen induced in vitro immunoglobulin and IgM rheumatoid factor production by peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis. J Rheumatol (1983) 0.92

Regulation of human immunoglobulin production in vitro by prostaglandin E2. Clin Exp Immunol (1982) 0.92

Joint destruction in rheumatoid arthritis: biological bases. Clin Exp Rheumatol (1997) 0.92

Studies of lymphocytes in rheumatoid arthritis. I. Uptake of 125I-heat aggregated human IgG by Fc-receptor bearing lymphocytes. Ann Rheum Dis (1978) 0.92

Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis. Ann Rheum Dis (1995) 0.92

High frequency of cord blood lymphocytes against mycobacterial 65-kDa heat-shock protein. Eur J Immunol (1992) 0.92

HLA class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared-epitope hypothesis accounts for the disease in only a minority of Greek patients. Arthritis Rheum (1992) 0.91

Natural killer cell activity in inflammatory joint disease. Clin Rheumatol (1983) 0.91

Limiting dilution analysis of proliferative T cell responses to mycobacterial 65-kDa heat-shock protein fails to show significant frequency differences between synovial fluid and peripheral blood of patients with rheumatoid arthritis. Eur J Immunol (1991) 0.91